Skip to main content
TipRanks
Go Ultimate75% OFF

Biogen (BIIB) AI Stock Analysis

5,092 Followers
BIIB

Biogen

(NASDAQ:BIIB)

Select Model
Rating:67Neutral
Price Target:$274.00▲(9.25% Upside)
Action:reiterated
Date:10/28/26

BIIB’s score is driven primarily by steady but pressured financial performance (solid cash flow and manageable leverage, offset by a clear TTM margin/FCF downshift). Technicals add support with strong trend strength above major moving averages, though momentum looks extended. The most significant drag is valuation (high P/E), while the earnings call meaningfully improves the outlook via raised EPS guidance, strong growth-portfolio momentum, and synergy/deleveraging progress.

Positive Factors
Growth Portfolio MomentumRapid growth in the newer portfolio is reducing reliance on Biogen’s legacy MS franchise and broadening its revenue base. The portfolio’s increasing contribution supports a more durable return to growth, provided adoption remains strong across its neurological and specialty products.
Negative Factors
Profitability CompressionThe sharp decline in operating and net margins weakens earnings durability even though revenue is growing modestly. Lower profitability reduces the cash available per dollar of sales and can constrain investment capacity if higher launch and development spending persists.

Biogen Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down Biogen’s sales across regions, showing where its drugs earn the most revenue and where growth or regulatory risk is concentrated. Useful for spotting heavy reliance on the U.S. market, exposure to differing reimbursement rules, and which regions offer room to expand with new approvals or label changes.

$0.00$500.00M$1.00B$1.50B$2.00B$2.50BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

International revenue shows a multi‑year erosion with intermittent rebounds and a pronounced late‑2025 trough—consistent with ex‑U.S. shipment timing and biosimilar/access pressure (TYSABRI) noted on the call—while the “Other” geography bucket has meaningfully strengthened into 2026 as Biogen’s growth portfolio and the Apellis assets begin contributing. The company’s guidance upgrade hinges on that mix shift: acquisitions and new product adoption offset regional weakness, but near‑term EPS and leverage risks persist until synergies and broader payer access (e.g., IQLIK, SPINRAZA high‑dose) materialize.

Data provided by:The Fly

Biogen (BIIB) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%50%BIIB+43.06%SPY+13.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$37.07B
Dividend Yield
―
Average Volume (3M)
1.08M
Price to Earnings (P/E)
105.6
Beta (1Y)
0.46
Revenue Growth
2.15%
EPS Growth
-78.55%
Country
US
Employees
7,500
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - General

Biogen Business Overview & Revenue Model

Company Description

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addre...

How the Company Makes Money

Biogen makes money primarily by selling prescription medicines and recognizing revenue from collaboration-related arrangements. 1) Product sales (core revenue stream) - Biogen’s largest revenue driver is net sales of its marketed therapies. This incl...

Biogen Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:-0.77%|Next Earnings Date:Feb 17, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Biogen reported double-digit revenue growth, accelerating growth-portfolio performance, rapid Appellis synergy capture, strong adoption of key products, record early-stage pipeline productivity, solid free cash flow, debt repayment, and higher 2026 EPS guidance. The main challenges were VUMERITY's formulary-driven decline, acquisition-related charges and higher operating expenses, expected Q4 inventory and revenue normalization, SYFOVRE discontinuation levels, and uncertainty around upcoming clinical readouts.

Positive Updates

Total Revenue Growth
Third-quarter total revenue was $2.8 billion, up 11% year over year, marking an acceleration in the top-line growth trajectory and benefiting from the Appellis acquisition.

Negative Updates

VUMERITY Revenue Decline
VUMERITY revenue was $192 million, down 11% year over year and 2% quarter over quarter. Revenue was affected by tighter Part D formulary management, and management expects this dynamic to continue affecting Part D drugs this year.

Company Guidance

Biogen expects to return to top line growth in 2026; full year 2026 non-GAAP diluted EPS guidance is between $12.20 and $13.00, with approximately $50 million of acquired IPR&D in the fourth quarter. Q4 global SPINRAZA revenue is expected to be up approximately a mid single digit percentage versus the fourth quarter of 25, Q4 VUMERITY revenue is expected to be roughly flat sequentially or up approximately a mid single digit percentage versus the fourth quarter of 25, and Q4 SYFOVRE revenue is expected to be up approximately a mid single digit percentage versus the $155 million reported by Appellis in the fourth quarter of 25; SKYCLARYS inventory of approximately $12 million and SYFOVRE inventory of approximately $11 million are expected to be drawn down in Q4. The Appellis transaction is expected to be less dilutive in 2026 and accretive to non GAAP diluted EPS in 2027, generating at least $250 million of run rate synergies by the end of 2027, while Biogen expects to repay the remaining $1.4 billion of term loans by the end of 27; at least 50% of covered lives are expected to have coverage for LEQEMBI iClick in both the initiation and maintenance administrations starting in 2027.

Biogen Financial Statement Overview

Summary

Financials are mixed: revenue is modestly higher in TTM (~3.5%) and cash generation remains solid (TTM operating cash flow ~$2.25B; free cash flow ~$2.42B, ~1.03x net income). However, profitability has weakened meaningfully versus prior years (TTM net margin ~8.4% and EBITDA margin ~19.7%), and free cash flow is down (~18% YoY). Leverage looks manageable (debt-to-equity ~0.44), but ROE has cooled (~4.5%), reflecting the margin downshift.

Income Statement

62Positive

Balance Sheet

70Positive

Cash Flow

68Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue10.30B9.89B9.68B9.84B10.17B10.98B
Gross Profit7.21B7.49B7.37B7.30B7.90B8.87B
EBITDA1.60B2.60B3.00B2.38B3.54B3.92B
Net Income347.50M1.29B1.63B1.16B3.05B1.56B
Balance Sheet
Total Assets32.05B29.44B28.05B26.84B24.55B23.88B
Cash, Cash Equivalents and Short-Term Investments1.30B3.82B2.38B1.05B4.89B3.80B
Total Debt7.80B6.95B6.63B7.34B6.61B7.60B
Total Liabilities13.13B11.18B11.33B12.05B11.17B12.92B
Stockholders Equity18.92B18.26B16.72B14.80B13.40B10.90B
Cash Flow
Free Cash Flow2.05B2.05B2.52B1.24B1.14B3.38B
Operating Cash Flow2.25B2.20B2.88B1.55B1.38B3.64B
Investing Cash Flow-5.50B-1.37B-799.20M-4.09B1.59B-563.70M
Financing Cash Flow776.60M-301.90M-683.50M137.00M-1.76B-2.09B

Biogen Technical Analysis

Technical Analysis SentimentPositive
Last Price250.79

Price Trends

50DMA234.73Positive
100DMA222.09Positive
200DMA205.87Positive

Market Momentum

MACD4.90Positive
RSI56.04Neutral
STOCH56.89Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIIB, the sentiment is Positive. The current price of 250.79 is above the 20-day moving average (MA) of 250.52, above the 50-day MA of 234.73, and above the 200-day MA of 205.87, indicating a bullish trend. The MACD of 4.90 indicates Positive momentum. The RSI at 56.04 is Neutral, neither overbought nor oversold. The STOCH value of 56.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BIIB.

Biogen Risk Analysis

Biogen disclosed 30 risk factors in its most recent earnings report. Biogen reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.The increasing use of AI-based software presents new risks and challenges and could adversely affect our business and reputation.Q4, 2024

Biogen Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BIIB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SNYSNY83Outperform$114.16B24.805.84%5.09%23.68%-30.90%
LLYLLY81Outperform$1.33T45.5483.65%0.49%45.51%50.48%
NVSNVS72Outperform$290.32B30.5224.24%2.98%1.64%-28.72%
ABBVABBV71Outperform$517.59B50.06-202.35%2.36%10.68%338.08%
JNJJNJ70Outperform$670.92B42.3019.55%1.89%7.81%-35.95%
BIIBBIIB67Neutral$37.07B105.591.86%―2.15%-78.55%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%20%40%BIIBLLYJNJNVSSNYABBVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BIIB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BIIBBiogen Inc.250.7982.6149.12%
LLYEli Lilly And Company1415.55378.5336.50%
JNJJohnson & Johnson278.7080.1140.34%
NVSNovartis AG159.1337.1630.46%
SNYSanofi SA47.530.521.10%
ABBVAbbvie292.8270.0431.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026